Study points to adiponectin pathway in equine laminitis: full analysis

A new Equine Veterinary Journal study suggests adiponectin receptor agonists may help protect equine lamellar tissue from endoplasmic reticulum stress, a pathway increasingly implicated in endocrinopathic laminitis. In cultured equine lamellar cells, the investigators found that AdipoRon, AICAR, and adiponectin reduced stress-marker expression after pharmacologic induction of endoplasmic reticulum stress, raising the possibility that adiponectin signaling could become a future therapeutic avenue for laminitis prevention or treatment. (eceim-congress.com)

The work fits into a longer shift in laminitis research away from viewing the condition only as a hoof problem and toward understanding it as a consequence of systemic metabolic disease in many horses. Earlier studies have documented endoplasmic reticulum stress and unfolded protein response activity in lamellar tissue from horses with naturally occurring endocrinopathic laminitis, supporting the idea that chronic metabolic signaling may directly damage the lamellae. Other groups have also investigated insulin and IGF-1 receptor signaling in lamellar cells, reinforcing the link between hyperinsulinemia and tissue-level injury. (pmc.ncbi.nlm.nih.gov)

According to the study abstract and conference reporting of related work from the same research group, the investigators used an in vitro model of equine lamellar endoplasmic reticulum stress and measured expression of GRP78, a commonly used stress marker. Treatments with AdipoRon, AICAR, and adiponectin reduced those markers compared with stressed controls. Because AdipoRon is a synthetic adiponectin receptor agonist and AICAR is an AMPK activator, the results also point toward metabolically relevant signaling pathways that may influence lamellar cell resilience under stress conditions. That said, the current report is preclinical and limited to cell culture, so it doesn't yet answer whether the effect will translate into meaningful outcomes in horses with naturally occurring disease. (eceim-congress.com)

Direct outside commentary on this specific paper appears limited so far, but the broader field has been moving in a similar direction. Reviews and clinical overviews have emphasized that endocrinopathic laminitis remains a major unmet need, with management still focused largely on correcting insulin dysregulation, dietary control, analgesia, and mechanical hoof support rather than disease-specific pharmacology. Experimental work on IGF-1 receptor blockade has suggested one possible targeted path, and Bamford and colleagues have separately highlighted the treatment gap in endocrinopathic laminitis. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the significance is less about an immediate treatment change and more about a potential new drug-development pathway. Adiponectin biology has long been tied to insulin sensitivity and metabolic health, and lower adiponectin signaling has been discussed in relation to laminitis risk and metabolic dysfunction in horses. If adiponectin receptor agonism can reduce lamellar stress responses, it could eventually offer a way to intervene closer to the tissue pathology itself, rather than only managing upstream endocrine triggers and downstream hoof damage. (sciencedirect.com)

There are also important caveats. In vitro stress reduction doesn't establish efficacy in the living horse, where laminitis involves vascular, inflammatory, endocrine, and biomechanical factors. Questions remain around drug delivery to lamellar tissue, dosing, off-target effects, duration of treatment, and whether intervention would be most useful for prevention in high-risk insulin-dysregulated horses or as an adjunct once laminitis is underway. Those translational hurdles have challenged other promising mechanistic findings in the field. (sciencedirect.com)

What to watch: Watch for the full paper's methods and data, follow-up ex vivo or in vivo studies, and any movement toward translational testing in endocrinopathic laminitis models. If the signal holds up, adiponectin receptor agonists could join a small but growing list of targeted candidates aimed at modifying laminitis biology rather than only managing its consequences. (eceim-congress.com)